Chemotherapy-Induced Activation of Hemostasis: Effect of a Low Molecular Weight Heparin (Dalteparin Sodium) on Plasma Markers of Hemostatic Activation

Summary

Purpose

To evaluate the effect of standard chemotherapeutic regimens on the hemostatic profile of patients with breast and lung carcinoma; and to evaluate the effect of a single dose of a low molecular weight (LMW) heparin, dalteparin sodium, administered prior to the chemotherapy on markers of hemostatic activation.

Patients and Methods

11 patients with breast cancer and 10 patients with lung cancer receiving systemic chemotherapy were studied. 10 breast cancer patients and 9 lung cancer patients completed at least 1 cycle of treatment and had all hemostatic studies. Patients had a complete hemostatic and prothrombotic profile performed at study initiation. Markers of hemostatic activation consisting of immunoassays for thrombin-antithrombin (TAT) complex and D-dimer were measured in plasma samples obtained prior to chemotherapy and at 1, 24 and 48 h after treatment. A 2500 U dose of dalteparin was given prior to the 2nd cycle of chemotherapy; 5000 U of dalteparin was given prior to the 4th treatment cycle.

Results

Chemotherapy resulted in statistically significant increases in TAT and D-dimer for the 1, 24 and 48 h plasma samples in both the breast and lung cancer patients for all cycles of chemotherapy given without LMW heparin. There were statistically significant increases in basal thrombin generation over the 4 cycles of treatment which was unrelated to active cancer. Both pretreatment doses of dalteparin effectively prevented increases in the markers of hemostatic activation. However, in the lung cancer patients, who had significantly increased basal thrombin generation, the 5000 U dose dalteparin was more effective.

Conclusion

Chemotherapy results in significant hemostatic activation in patients with breast and lung cancer. The effect of treatment appears to be cumulative. A single dose of LMW heparin administered prior to therapy can suppress hemostatic activation.

This project was funded by a grant from the Pharmacia corporation

Keywords

Cancer - chemotherapy - hemostatic activation - thrombosis

• References

• 1 Trousseau A. Phlegmasia alba dolens. In: Clinique Medicale de l’Hotel- Dieu de Paris. Paris: JB Balliere et Fils; 1865. 3: 654-712.
• 2 Sack GH, Levin J, Bell W. Trousseau’s Syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasm: clinical, pathophysiologic and therapeutic features. Medicine (Baltimore) 1977; 56: 1-37.
• 3 Rickles FR, Levine MN, Dvorak HF. Abnormalities of Hemostasis in Malignancy in Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th Edition. Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN. Philadelphia: Lippincott Williams & Wilkins; 2000: 1131-52.
• 4 Lyman GH, Bettigole RE, Robson E, Ambrus JL. Fibrinogen kinetics in patients with neoplastic disease. Cancer 1978; 41: 1113-22.
• 5 Yoda Y, Abe T. Fibrinopeptide A (FPA) levels and fibrinogen kinetics in patients with malignant disease. Thromb Haemost 1981; 46: 706-9.
• 6 Edwards RI, Rickles FR, Cronlund M. Abnormalities in blood coagulation with cancer. Mononuclear tissue factor generation. J Lab Clin Med 1981; 98: 917-28.
• 7 Bertomeu MC, Gallo S, Lauri D, Levine MN, Orr FW, Buchanan MR. Chemotherapy enhances endothelial cell reactivity to platelets. Clin Expl Metastasis 1990; 08: 511-8.
• 8 Rickles FR, Levine M, Edwards RL. Hemostatic alterations in cancer patients. Cancer Metastasis Rev 1992; 11: 237-48.
• 9 Clarke-Pearson DL, Creasman WT, Coleman RE, Synan IS, Hinshaw WM. Perioperative external pneumatic calf compression as thromboembolism prophylaxis in gynecologic oncology: report of a randomized trial. Gynecol Oncol 1984; 18: 222-32.
• 10 Clagett GP, Reisch JS. Prevention of venous thormboembolism in general surgical patients. Ann Surg 1988; 208: 227-40.
• 11 Raaf J. Results from the use of 826 vascular access devices in cancer patients. Cancer 1985; 55: 1312-21.
• 12 Weitz IC, Israel VK, Liebman HA. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden. Cancer 1997; 79: 2024-7.
• 13 Weiss RB, Tormey DC, Holland JF, Weinberg VE. Venous thrombosis during multimodal treatment of primary breast carcinoma. Cancer Treat Rep 1981; 63: 677-9.
• 14 Levine MN, Gent M, Hirsch J, Arnold A, Goodyear MD, Hryniuk W, DePauw S. The thrombogeneic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988; 318: 404-7.
• 15 Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991; 09: 286-94.
• 16 Goodnough LT, Saito H, Manni A, Jones PK, Pearson OH. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer 1984; 54: 1264-8.
• 17 Edwards RL, Klaus M, Matthews E, McCullen C, Bona RD, Rickles FR. Heparin abolishes the chemotherapy-induced increase in plasma Fibrinopeptide A Levels. Am J Med 1990; 89: 25-8.
• 18 Levine M, Hirsch J, Gent M, Arnold A, Warr D, Falanga A, Samosh M, Bramwell V, Pritchard KI, Stewart D, Goodwin P. Double-blind randomized trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343: 886-9.
• 19 Weitz JI. Low molecular weight heparins. N Engl J Med 1997; 337: 668-98.
• 20 Kakkar VV, Cohen AT, Edmonson RA, Phillips MJ, Cooper DJ, Das SK, Maher KT, Sanderson RM, Ward VP, Kakkar S. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 1993; 341: 259-65.
• 21 Rickles FR, Edwards RL, Barb C, Cronlund M. Abnormalities of blood coagulation in patients with cancer. Fibrinopeptide A generation and tumor growth. Cancer 1983; 51: 301-7.
• 22 Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau’s syndrome revisited. Blood 1983; 62: 14-31.
• 23 Falanga A, Ofosu FA, Cortelazzo S, Delaini F, Consonni R, Caccia R, Longatti S, Maran D, Rodeghiero F, Pogliani E, Marassi A, D’Angelo A, Barbui T. Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery. Br J Haematol 1993; 85: 745-50.
• 24 Nevasaari K, Heikkinen M, Taskinen PJ. Tamoxifen and thrombosis. Lancet 1978; 02: 946-7.
• 25 Lipton A, Harvey H, Hamilton RW. Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat Rep 1984; 68: 887-9.
• 26 Blackard CE, Byar DP, Jordan WP. Orchiectomy for advanced prostate carcinoma. Urology 1973; 01: 553-61.
• 27 Doll DC, Ringenberg QS, Yarbro JW. Vascular toxicity associated with antineoplastic agents. J Clin Oncol 1986; 04: 1405-17.
• 28 Falanga A, Levine MN, Consonni R, Gritti G, Delaini F, Oldani E, Julian JA, Barbui T. The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: Results from a randomized trial. Thromb Haemost 1998; 79: 23-7.